 Orphazyme AS NASDAQ: ORPH announced that results from a Phase 23 trial of arimoclomol in Niemann-Pick disease type C NPC had been published in the peer-reviewed Journal of Inherited Metabolic Disease JIMD. Arimoclomol is an investigational heat-shock protein amplifier. 